Company profile

Clay B. Siegall
Incorporated in
Fiscal year end
IRS number

SGEN stock data

FINRA relative short interest over last month (20 trading days) ?


6 Feb 20
19 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 289.8M 213.26M 218.45M 195.2M
Net income 25.83M -91.91M -79.24M -13.33M
Diluted EPS 0.14 -0.55 -0.49 -0.08
Net profit margin 8.91% -43.10% -36.27% -6.83%
Operating income -38.41M -89.78M -38.71M -53.64M
Net change in cash 81.1M 129.35M -20.16M 6.08M
Cash on hand 274.56M 193.47M 64.11M 84.27M
Cost of revenue
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 916.71M 654.7M 482.25M 418.15M
Net income -158.65M -222.69M -125.53M -140.11M
Diluted EPS -0.96 -1.41 -0.88 -1
Net profit margin -17.31% -34.01% -26.03% -33.51%
Operating income -220.55M -260M -195.8M -142.73M
Net change in cash 196.38M -82.76M 52.27M 6.42M
Cash on hand 274.56M 78.19M 160.95M 108.67M
Cost of revenue 34.77M 28.17M

Financial data from company earnings reports

95.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 322 318 +1.3%
Opened positions 43 32 +34.4%
Closed positions 39 57 -31.6%
Increased positions 119 102 +16.7%
Reduced positions 94 117 -19.7%
13F shares
Current Prev Q Change
Total value 66.01B 53.7B +22.9%
Total shares 164.25M 159.99M +2.7%
Total puts 781.9K 472.67K +65.4%
Total calls 444.3K 433.9K +2.4%
Total put/call ratio 1.8 1.1 +61.6%
Largest owners
Shares Value Change
Baker Bros. Advisors 50.06M $4.27B 0.0%
Capital International Investors 17.88M $1.53B +25.1%
Wellington Management 15.87M $1.36B +10.4%
Primecap Management 13.23M $1.13B -6.6%
Vanguard 10.67M $911.47M +13.6%
N Price T Rowe Associates 9.07M $774.38M +10.5%
BLK BlackRock 8.59M $733.96M +5.2%
Baillie Gifford & Co 6.56M $560.33M -1.8%
STT State Street 3.29M $281.15M +3.9%
Matrix Capital Management 1.6M $136.5M -49.1%
Largest transactions
Shares Bought/sold Change
Capital International Investors 17.88M +3.59M +25.1%
Matrix Capital Management 1.6M -1.54M -49.1%
Wellington Management 15.87M +1.5M +10.4%
Capital Guardian Trust 0 -1.3M EXIT
Vanguard 10.67M +1.28M +13.6%
Capital International 1.24M +1.12M +967.7%
Primecap Management 13.23M -933.89K -6.6%
N Price T Rowe Associates 9.07M +864.17K +10.5%
First Trust Advisors 926.08K -858.56K -48.1%
MN Manning & Napier 564.92K -461.95K -45.0%

Financial report summary

  • Risks Related to Our Business
  • Our success also depends on our ability to obtain regulatory approvals of our product candidates and of our current products in additional territories, as well as our ability to expand the labeled indications of use for our current products, and, if the requisite approvals are obtained, our ability to successfully launch and commercialize our products in their approved indications. Our inability to do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
  • Reports of adverse events or safety concerns involving our products or product candidates could delay or prevent us from obtaining or maintaining regulatory approvals or could negatively impact sales of our products or the prospects for our product candidates.
  • Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products.
  • Clinical trials are expensive and time consuming, may take longer than we expect or may not be completed at all, and their outcome is uncertain.
  • Our product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products.
  • The successful commercialization of our products and our product candidates will depend on a variety of factors, including the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies, and the acceptance of our products by the medical community and patients.
  • Healthcare law and policy changes may have a material adverse effect on us.
  • Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.
  • We depend on collaborative relationships with other companies to assist in the development and commercialization of our products and some of our product candidates and for the development and commercialization of other product candidates utilizing or incorporating our technologies. If we are not able to locate suitable collaborators or if our collaborators do not perform as expected, this may negatively affect our ability to commercialize our products, develop and commercialize our product candidates and/or generate revenues through technology licensing, or may otherwise negatively affect our business.
  • We face intense competition and rapid technological change, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.
  • Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our stock could decline.
  • We have a history of net losses. We expect to continue to incur net losses and may not achieve future profitability for some time, if at all.
  • If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.
  • Risks associated with our expanding operations in foreign countries could materially adversely affect our business.
  • We currently rely on third-party manufacturers and other third parties for production of our drug products and our dependence on these manufacturers may impair the continued development and commercialization of our products and product candidates.
  • We are using our own manufacturing facility to support our clinical-stage pipeline, and we could encounter challenges in operating this facility.
  • We have engaged in, and may in the future engage in, strategic transactions that increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
  • To date, we have depended on a small number of collaborators for a substantial portion of our revenue. The loss of any one of these collaborators or changes in their product development or business strategy could result in a material decline in our revenue.
  • We are dependent upon a small number of distributors for a significant portion of our net sales, and the loss of, or significant reduction or cancellation in sales to, any one of these distributors could adversely affect our operations and financial condition.
  • We are subject to various state and federal and foreign laws and regulations, including healthcare, data protection and privacy laws and regulations, that may impact our business and could subject us to significant fines and penalties or other negative consequences.
  • Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • As we continue to expand our operations internationally, we are subject to an increased risk of conducting activities in a manner that violates applicable anti-bribery or anti-corruption laws. We are also subject to foreign laws and regulations covering data privacy and the protection of health-related and other personal information. These laws and regulations could create liability for us or increase our cost of doing business, any of which could have a material adverse effect on our business, results of operations and growth prospects.
  • Any failures or setbacks in our ADC development program would negatively affect our business and financial position.
  • We have been and may in the future be subject to litigation, including securities-related litigation, litigation pertaining to the conduct of our business, and litigation in connection with the Cascadian Acquisition and potential future strategic transactions. Such litigation could result in substantial damages and may divert management’s time and attention from our business.
  • We may need to raise additional capital that may not be available to us.
  • We and our collaborators rely on license agreements for certain aspects of our products and product candidates and technologies such as our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from continuing to develop and commercialize our products and product candidates.
  • If we are unable to enforce our intellectual property rights or if we fail to sustain and further build our intellectual property rights, we may not be able to successfully commercialize our products or any future products and competitors may be able to develop competing therapies.
  • We may incur substantial costs and lose important rights or may not be able to continue to commercialize our products or to commercialize any of our product candidates that may be approved for commercial sale as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be required to obtain patent and other intellectual property rights from others.
  • If we lose our key personnel or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer.
  • Product liability and product recalls could harm our business, and we may not be able to obtain adequate insurance to protect us against product liability losses.
  • Our operations involve hazardous materials and are subject to environmental, health and safety controls and regulations.
  • If any of our facilities are damaged or our clinical, research and development or other business processes are interrupted, our business could be seriously harmed.
  • If we experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected.
  • Increasing use of social media could give rise to liability.
  • Legislative actions and new accounting pronouncements are likely to impact our future financial position or results of operations.
  • The potential future impairment of in-process research and development and goodwill related to the Cascadian Acquisition may negatively affect our results of operations and financial position.
  • Risks Related to Our Common Stock
  • Our stock price is volatile and our shares may suffer a decline in value.
  • Substantial future sales of shares of our common stock or equity-related securities could cause the market price of our common stock to decline.
  • Our existing stockholders have significant control of our management and affairs.
  • Anti-takeover provisions could make it more difficult for a third party to acquire us.
Content analysis ?
H.S. sophomore Avg
New words: absolute, agreeable, ALT, antidiarrheal, AST, back, balversa, baseline, BeiGene, belantamab, Certification, cessation, CI, Circuit, Cline, CMC, complement, Confidence, confounded, contend, daniel, Darren, david, declaration, declaratory, dedicate, Delinquent, dry, duly, dysfunction, dysgeusia, elevation, England, Enhertu, epidermal, erythrodysaesthesia, estate, EV, Excellence, exemption, expiry, exploratory, eye, faster, feedback, felix, FGFR, fibroblast, formal, formally, formatted, gryska, headquartered, herewith, HR, immunomodulatory, implicit, incremental, Inline, innate, Interval, invasive, Jean, john, Journal, kidney, lawfully, lippman, Liu, liver, MAA, marc, marked, masking, Mississauga, moderate, motor, MOUNTAINEER, multinational, muscle, naive, nancy, navigate, neoadjuvant, nonexclusive, OCE, opportunistic, orwin, PADCEV, PADCEVTM, Page, permanently, perpetuity, play, pneumonia, pocket, Polivy, PolivyTM, PPE, proteasome, publicly, pursuit, qualification, quantity, question, RAS, real, RECIST, redacted, reliance, remanded, Robin, RTOR, rulemaking, shareholder, shrank, simonian, Singapore, steroid, stimulatory, suspected, tagged, taxane, Taylor, text, thereunto, tied, topline, traditionally, transaminase, trbreatment, TV, uncover, undersigned, unresectable, upheld, welch, widespread, XBRL
Removed: ACTR, advice, AG, amend, amortize, anemia, anniversary, ASH, Assuming, attached, attractive, began, bendamustine, BTD, calculating, CASCADE, categorization, Celldex, CHOP, CHP, coincide, combine, constipation, CTCL, digit, DLBCL, dose, eleven, employed, enactment, evaluable, fatal, formed, geographic, germ, initiate, initiation, integration, IRR, linking, mesothelioma, MMAE, monomethyl, neutrophil, notwithstanding, penetration, phased, PML, preclude, prepare, promulgation, prorated, quantify, rare, recommended, remission, renew, restore, resubmit, salvage, sBLA, SPA, successive, temporarily, tenant, testicular, tiered, varied, viable, vincristine